Workshop speakers

Benoit Arsenault

Quebec, Canada

ICCR-EAS Joint Session

SSBs: A simple lifestyle marker associated with cardiometabolic health

Dr Benoit Arsenault is an Assistant Professor at the Department of Medicine at Université Laval and a research scientist at the Québec Heart and Lung Institute in Québec City, Canada. The research of Dr Arsenault’s team focuses on the impact of lifestyle, genetics and pharmacotherapy on lipoprotein metabolism, cardiometabolic risk and cardiovascular diseases such as calcific aortic valve stenosis. He has authored or co-authored more than 80 peer-reviewed scientific manuscripts in major medical, scientific and cardiology journals and now holds a junior scholar award from the Fonds de recherche du Québec: Santé. He has received several distinctions such as the Young Investigator Clinical Science Award of the European Society of Cardiology in 2011.

Maurizio Averna

Palermo, Italy

EBAC ACCREDITATION PENDING

Lysosomal acid lipase deficiency – an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction

Maurizio Averna was born in Palermo, Italy, in 1952. Degree in Medicine in 1976, University of Palermo, Italy. Specialties in Internal Medicine, Diabetes and Metabolic Diseases, Clinical Biochemistry (1981, 1985 and 1991). Clinical and Research Fellow at the Lipid Research Division, Washington University, St. Louis, U.S.A. (1991-1993).

Full Professor of Internal Medicine, Director of the Residency Program in Internal Medicine, Head of the Unit of Clinical, Respiratory and Emergency Medicine, Head of the Regional Centre of Rare Inherited Metabolic Diseases all at the University of Palermo, Italy

His main interests are biochemistry, genetics and molecular biology of lipids and lipoproteins.

Steven J. Bensinger

Los Angeles, USA

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

Cholesterol biosynthetic flux and immunity

Dr. Bensinger is an Associate Professor of Microbiology, Immunology, and Molecular Genetics, and of Molecular and Medical Pharmacology. He received his Veterinary Medical Degree and Doctor of Philosophy in Immunology from the University of Pennsylvania. Dr. Bensinger’s thesis work was completed under the mentorship of Dr. Laurence Turka, and focused on the development and function of CD4 regulatory T cells. Dr. Bensinger subsequently completed a postdoctoral fellowship in the laboratory of Dr. Peter Tontonoz at UCLA, where he examined the impact of lipid metabolism on lymphocyte function and adaptive immunity. Since establishing his own laboratory at UCLA, Dr. Bensinger has emerged as a leader in understanding the influence of lipid metabolism on the immune system. Dr. Bensinger currently serves as Director of Immunology, Inflammation, Infection and Transplantation (I3T) Research at UCLA David Geffen School of Medicine.

Eric Bruckert

Paris, France

EBAC ACCREDITATION PENDING

Typical clinical cases: who may benefit?

Case 2

Christopher D. Byrne

Southampton, United Kingdom

ICCR-EAS Joint Session

Ectopic fat, non-alcoholic fatty liver disease and cardiometabolic health?

Chris Byrne is Professor of Endocrinology & Metabolism at University of Southampton, UK. He has published > 250 peer reviewed publications and three books, related to metabolic syndrome, obesity and non alcoholic fatty liver disease. In 2012, he was awarded the Dorothy Hodgkin prize by Diabetes UK. He collaborates with colleagues around the globe and has MRC grant support for collaborative research with colleagues in Seoul and Edinburgh. He was the expert diabetologist advisor to the UK National Institute for Care Excellence NAFLD Guidelines and is Principal Investigator within the Southampton National Institute for Health Research Biomedical Research Centre.

André C. Carpentier

Quebec, Canada

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

Fatty acid metabolism in the human heart

Dr. Carpentier is the recipient of the GSK Research Chair in Diabetes and professor and clinician scientist in the Department of Medicine at the Université de Sherbrooke. He is the director of the Province of Quebec Research Network on Cardiometabolic Health, Diabetes and Obesity.

His research interests include postprandial fatty acid metabolism, brown adipose tissue metabolism in energy homeostasis and type 2 diabetes and mechanisms of bariatric surgery to treat diabetes. He has published more than 110 peer-reviewed manuscripts and is the recipient for >30 awards. He has been elected Fellow of the Canadian Academy of Health Sciences in 2015.

Alberico L. Catapano

Milan, Italy

ADVANCED CLINICAL SEMINARS

Summary and introduction of guidelines

ADVANCED CLINICAL SEMINARS

Case and panel discussion

ADVANCED CLINICAL SEMINARS

On the panel:

Recapturing the ESC/EAS Guideline recommendations

Roundtable and Q&A

Alberico L. Catapano was born in Milano in 1952. Received degree from the University of Milano in 1975 and a specialization in Clinical Pharmacology in 1979. From 1972 been involved in the field of Atherosclerosis, Lipids, Lipoproteins and genetic dislypidaemias. From the scientific standpoint Prof. Catapano has made landmark observations regarding the role of HSP’s and of Petranxins in Atherogenesis and on the role of HDL in the modulation of the immune response. Alberico Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).

Professor Catapano is Past President of the European Atherosclerosis Society (EAS), the Chairman of EAS Educational, Guidelines & Corporate Activities Committees and the Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis ; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.

He has authored more than 340 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.

M. John Chapman

Paris, France

EPIDEMIOLOGY, DIAGNOSIS, PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

HDL-cholesterol and cardiovascular disease: rethinking our approach

KEYNOTE LECTURE

Keynote Lecture: Mechanistic insights into innovative therapeutics in lipid lowering in vivo

COMMUNICATION SESSIONS

LDL is causal to atherosclerosis

COMMUNICATION SESSIONS

What do FOURIER data mean for clinical practice?

M. John Chapman BSc (Hons), PhD, DSc, FESC, is Research Professor at the University of Pierre and Marie Curie,  Director Emeritus of the Dyslipidemia and Atherosclerosis Research Unit, National Institute for Health and Medical Research (INSERM), at the Pitié-Salpétrière University Hospital in Paris, France, and Past-President of the European Atherosclerosis Society (EAS). Professor Chapman undertook his undergraduate studies at Aberdeen University and the Middlesex Hospital Medical School, University of London. He subsequently trained in cardiovascular lipidology at the Cardiovascular Research Institute of the University of California Medical Center, San Francisco, and at the Gladstone Foundation for Cardiovascular Disease in the same city. As President of  EAS from 2009 to 2013, he  actively supported the development of new Joint Guidelines for the Management of Dyslipidemia with the European Society of Cardiology launched in 2011. As Co-Chair of the EAS Consensus Panels and Consensus Papers, he has spearheaded initiatives on Lipoprotein Lp(a) and on atherogenic high triglyceride / low HDL  dyslipidemia as  major cardiovascular risk factors, on the underdiagnosis and undertreatment of heterozygous familial hypercholesterolemia (FH), on homozygous FH, on FH in children and adolescents with emphasis on optimal detection and treatment, on the genetics of  hypertriglyceridemic states,  on plant sterols and stanols in the management of dyslipidemia and prevention of cardiovascular disease, and most recently on intolerance to statin therapy with a focus on statin-associated muscle symptoms.

John is Associate European Editor of “Pharmacology and Therapeutics”, and a member of the Editorial Boards of “Arteriosclerosis, Thrombosis and Vascular Biology”, “Atherosclerosis”, “Vascular Pharmacology” and “Future Cardiology”. He is Co-Chair of the PCSK9 Education and Research Forum, and Chair of the ASPIRE Research Awards initiative  on PCSK9 biology in health and disease.  He has authored numerous publications and book chapters, and in 2012, co-authored an authoritative treatise on High Density Lipoproteins, entitled “HDL : Structure, Metabolism, Function and Therapeutics” (Wiley). Prof Chapman has presented plenary conferences worldwide as part of his dedication to international educational initiatives in lipoprotein biology and the pathophysiology of atherosclerotic vascular disease.  

His research has contributed to further understanding of the metabolic and structural heterogeneity of LDL and Lp(a) particles at the interface with their atherogenicity , and to structure-function relationships in HDL subpopulations in healthy subjects and in dyslipidemic states associated with high cardiovascular risk. The mechanisms of action of  pharmacological agents (statins, fibrates, CETP inhibitors, PCSK9 inhibitors) in attenuating atherogenic dyslipidemia are a central focus of his interests. His present research is focussed on (i) the intravascular metabolism  and pharmacotherapeutic modulation of the atherogenic apoB-containing lipoproteins, and (ii) the structural heterogeneity, molecular composition (proteome and lipidome) and functionality of native and recombinant HDL  in health and disease, with a view to optimisation of their anti-atherosclerotic potential.

Prof Chapman received a Distinguished Career Award from the International Atherosclerosis Society for his contributions to the field of HDL biology. In 2011, John was awarded Prizes for Scientific Excellence by INSERM. Prof Chapman is Laureate of the European Lipid Science Award for 2014, and  Laureate of the Antonio M. Gotto Jr Award in Atherosclerosis Research from the International Atherosclerosis Society for 2015.

Renata Cifkova

Prague, Czech Republic

ADVANCED CLINICAL SEMINARS

On the panel:

Prof. Cifkova Renata, MD, PhD, FESC
Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic

Renata Cifkova completed her medical education at Charles University in Prague and in 1986 earned a PhD in internal medicine with special emphasis on cardiology.

In 1989-1992, she was a Postdoctoral Fellow at the Faculty of Medicine, Memorial University, St. John’s, Newfoundland, Canada. In 1992, Dr. Cifkova was appointed Head, Department of Preventive Cardiology, Institute for Clinical Experimental Medicine, Prague, Czech Republic.

Her main research interests are epidemiology of cardiovascular risk factors, primary and secondary prevention of cardiovascular disease, and clinical trials in this field.

Giovanni Corrao

Milan, Italy

EBAC ACCREDITATION PENDING

The value of generic medicines

Professor Corrao currently carries out his research activity at the Division of Biostatistics, Epidemiology and Public Health, Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy. He is member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (coordinated by the European Medicines Agency) and of two Initiatives promoted by the Italian Health Ministry (the Bridge collaborative project and the working group for the development of indicators of care pathways).

His main research interest focuses on statistical models and epidemiological designs for generating evidence in the fields of healthcare research and pharmacoepidemiology by using health electronic archives.

He manages for the University of Milano-Bicocca 11 collaborative research projects supported from the European Community (3 projects), European Medicine Agency (1 project), Italian Medicines Agency (5 projects), and Italian Health Ministry (2 projects).

To date, he is Author / Co-author of 253 papers (PUBMED indexed) with 14,255 total citations and H-index 60 (Source Google Scholar).

Guy De Backer

Gent, Belgium

ADVANCED CLINICAL SEMINARS

Case and panel discussion

ADVANCED CLINICAL SEMINARS

On the panel:

Guy G. De Backer, MD, PhD, eFESC, eFACC
Honorary Professor of Medicine, Ghent University, Ghent, Belgium

Guy De Backer graduated in 1968 as medical doctor at the University of Ghent, Belgium. He holds special degrees in cardiology, in cardiac rehabilitation and in public health. In 1979 he was awarded with a PhD in epidemiology at Ghent University with a dissertation based on results from the Belgian Heart Disease Prevention Project.

From 1988 onwards he was professor of medicine at Ghent University chairing the Department of Public Health from 1989-2009. At the University Hospital in Ghent he has been chairing the Cardiac Rehabilitation centre from 1983-2009 and the Department of Cardiology from 2007-2009.

At the ESC level he chaired the Working group on epidemiology and prevention in 1990-1992 and from 1994 until now he has been involved in numerous guidelines on CVD prevention, dyslipidaemia and arterial hypertension.

Guy De Backer is a member and the past-chairman (1996-2009) of the Superior Health Council of Belgium and a member and the past-president (2007-2010) of the Royal Academy of Medicine of Belgium.

Marc Dweck

Edinburgh, United Kingdom

ADVANCED CLINICAL SEMINARS

PET/MRI

Dr Marc Dweck is a British Heart Foundation Senior Lecturer and Consultant Cardiologist at the University of Edinburgh. His main research interests are in the application of multi-modality  imaging techniques to the study of cardiovascular disease. His training has included international imaging fellowships at the Royal Bromtpon Hospital London (CMR); John’s Hopkins Medical Centre, Baltimore (CT); Cedars Sinai Medical Center Los Angeles (PET, CMR, CT) and currently Mount Sinai Hospital, New York (PET/CT, PET/MR). He is the recipient of multiple internation research awards (e.g. Sir Jules Thorn Award; Young Investigator Award, ACC; Parmley Prize, JACC; Young Research Workers Prize, RSNA) and he is the PI for two recently funded randomised control trials in aortic stenosis: SALTIRE 2 and EVOVLED-AS.

Brian A. Ference

Beijing/Detroit, China/USA

EPIDEMIOLOGY, DIAGNOSIS, PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

Using naturally randomized genetic evidence to understand heritability of coronary artery disease?

EBAC ACCREDITATION PENDING

Life time exposure to LDL-cholesterol is it the key to CVD risk?

Dr. Brian A. Ference is a cardiologist and genetic epidemiologist who was educated and trained at Harvard, Yale, Oxford and Cambridge Universities.  He is currently Associate Professor of Medicine; Clinical Chief of the Division of Cardiovascular Medicine; and Director of the Cardiovascular Genomic Research Center at Wayne State University.  His research focuses on using Mendelian randomization studies to generate naturally randomized evidence to fill evidence gaps; personalize the prevention of cardiovascular disease; and accelerate the drug discovery and development process by validating potential drug targets, informing the design of clinical trial programs and anticipating the results of randomized trials. 

Edward Fisher

New York, USA

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

Regression of atherosclerosis: from mechanisms to treatment

Dr. Edward A. Fisher is the Charney Professor of Cardiovascular Medicine as well as director of the vascular biology research program and of the Preventive Cardiology Center, all at the NYU School of Medicine. His research has focused on the cell biology of VLDL formation and apolipoprotein B100 degradation, the regression of atherosclerosis, and the application of nanoparticles for the imaging and therapy of arterial plaques. He received his MD from NYU, his clinical training at Duke and Harvard, and a PhD from MIT for a thesis under the direction Prof. Jan Breslow.

Gordon A. Francis

Vancouver, Canada

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

The importance of cholesterol in driving SMC trans differentiation in diseased plaque

Dr. Francis is a Professor of Medicine (Endocrinology and Metabolism), Associate Director of the Centre for Heart Lung Innovation, and Director of the Healthy Heart Program Prevention Clinic at the University of British Columbia in Vancouver. His research focuses on mechanisms of formation of HDL, particularly the role of lysosomally-derived cholesterol in the regulation of ABCA1. His group have recently found smooth muscle cells comprise the majority of foam cells in both human and mouse atherosclerosis, and that SMC foam cells in both species exhibit a reduction of ABCA1 expression not seen in macrophage foam cells.

Daniel Gaudet

Montreal, Canada

SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY

The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

In clinical practice – what data? Which patients ?

Panel discussion

Daniel Gaudet is Professor of Medicine at Université de Montréal, Canada. He founded the Université de Montréal Community Genomic Medicine Center, the Lipid Research Group, as well as the ECOGENE-21 research group. Dr. Gaudet is currently the scientific director of the Genome Quebec Biobank. His research interests focus on rare genetic lipid disorders and their associated impact on risk for cardiovascular disease, type 2 diabetes, pancreatitis and metabolic consequences to obesity. Dr. Gaudet was the recipient of the Genesis Genome Quebec Biotechnology of Tomorrow Award in 2012.

Christopher Glass

San Diego, USA

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

Genome-wide approaches to understanding roles of macrophages in atherosclerosis and metabolic disease

Dr. Glass received M.D. and Ph.D. degrees from UC San Diego and performed internship and residency training in Internal Medicine at Brigham and Women’s Hospital. He returned to UC San Diego for fellowship training in Endocrinology and Metabolism and then joined the UC San Diego faculty. He is currently Professor of Cellular and Molecular Medicine and Professor of Medicine at UC San Diego. Dr. Glass has had a long-standing interest in elucidating the molecular mechanisms by which sequence specific transcription factors, co-activators and co-repressors regulate the development and function of macrophages in health and disease. His current studies use a combination of genetics and genomics to define molecular mechanisms specifying transcriptional regulatory elements that establish macrophage identity and cell-specific responses to environmental signals. Dr. Glass’ laboratory is currently applying these approaches to understand pathological programs of macrophage gene expression that promote the development of atherosclerosis, diabetes, cancer and neurodegenerative diseases.

Imo Hoefer

Utrecht, Netherlands

ESC-EAS Joint Session

Hematological parameters as predictors of mortality, events and complications

Imo Hoefer works as Associate Professor at the Laboratory of Clinical Chemistry and Hematology and the Experimental Cardiology Laboratory at the University Medical Center Utrecht. He focuses on improvement of cardiovascular disease diagnosis, prediction and therapy applying big data, biomarkers and translational preclinical models of human disease. Since 2008, he is nucleus member and current past-chair of the ESC Working Group on Atherosclerosis and Vascular Biology and member of the ESC Council on Basic Cardiovascular Science.

Jay D. Horton

Dallas, USA

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

Focus on SREBPs

Dr. Jay D. Horton is a Professor of Internal Medicine and Molecular Genetics, Chief of the Division of Digestive and Liver Diseases, and Director of the Center for Human Nutrition at UT Southwestern. He obtained his B.S. and M.D. degrees from the University of Iowa and completed his Internal Medicine residency, gastroenterology fellowship, and Howard Hughes post-doctoral fellowship at UT Southwestern. Dr. Horton’s research interests are in determining how transcriptional regulators of fat metabolism contribute to the development of fatty liver and delineating the function of PCSK9, a protein secreted into the blood that regulates LDL receptors in liver.

G. Kees Hovingh

Amsterdam, Netherlands

ADVANCED CLINICAL SEMINARS

HoFH International Collaboration – HICC registry

G Kees Hovingh (1974) received his medical degree at the Univerity of Groningen in 2000, his PhD in 2005 and his MBA in 2016. Hovingh is an internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and visiting professor at Imperial college in London, UK. Hovingh is head of the clinical trial unit and involved in a large number of clinical trials, mainly focused on novel therapies to combat (the consequences of) dyslipidemia. Hovingh gained his interest in genetic lipidology via research conducted at the AMC, and he co-authored over 170 publications (Hirsh factor: 38).

Through this research, Dr Hovingh has identified mutations in a large number of pivotal genes in lipid metabolism in patients with extreme dyslipidemia phenotypes. Overall aim of the unraveling of the molecular pathology in patients is to identify novel and innovative therapeutic pathways to reduce the burden of dyslipidemia and cardiovascular disease.

Sander Kersten

Wageningen, Netherlands

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

The role of ANGPTL3 in controlling lipoprotein metabolism

Dr. Sander Kersten received his PhD in Nutritional Biochemistry from Cornell University in 1997. After a postdoctoral stay in the laboratory of Dr. Walter Wahli at the University of Lausanne, Switzerland, he moved to Wageningen in 2000, initially as a fellow of the Royal Netherlands Academy of Arts and Sciences and later as associate professor. Since 2011 he is full professor in Molecular Nutrition and since 2014 chair of the Nutrition, Metabolism and Genomics group. His current research interests revolve around the metabolism and regulatory influence of lipids, with a focus on key regulatory proteins such as PPARs and ANGPTL4.

Dagmar Kratky

Graz, Austria

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

Lipases and lipolysis in cellular lipid metabolism and signaling

Dagmar Kratky is Professor for Biochemistry at the Medical University of Graz, Austria. The research interests of her group focus on lipid and energy metabolism in non-adipose tissues and cells. Over the past years, her laboratory has successfully explored the role of neutral lipid hydrolases in various blood cell types including macrophages and neutrophils. D. Kratky utilizes mutant mouse models with loss or overexpression of lipases or lipid-synthesizing enzymes to investigate the impact of the respective enzymes on whole-body lipid and energy metabolism and to understand molecular mechanisms causing abnormalities in lipid and lipoprotein metabolism associated with the development of chronic inflammatory disorders such as atherosclerosis. In addition, she is interested in cell and tissue autonomous functions of the respective enzymes.

Eicke Latz

Bonn, Germany

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

Cholesterol crystals and inflammation

Eicke Latz studied Medicine in Göttingen and Berlin and worked as an intensive care physician at the Charité Hospital in Berlin. Starting 2000 he received post-doctoral training at Boston University and UMass Medical School in the Golenbock laboratory. He joined Faculty in 2006 and is currently adjunct Professor at UMass Medical School. In 2010 he founded the Institute of Innate Immunity at the University of Bonn in Germany. He is furthermore holds an Adjunct Professorship at the Centre for Molecular Inflammation Research at the Norwegian Technical University in Trondheim and he heads the Unit Innate Immunity in Neurodegeneration at the German Center for Neurodegenerative Diseases (DZNE) in Bonn. His research focuses on identifying the most proximal mechanisms of innate immune activation in chronic inflammatory diseases. Dr. Latz is listed in the World’s Most Influential Minds by Thompson Reuters and is a highly cited scientist in immunology since 2014.

Lars Lind

Uppsala, Sweden

ESC-EAS Joint Session

Temporal versus one-time biomarker measurements

Lars Lind is Professor of Medicine and the Linnaeus chair of Medicine at Uppsala University. Consultant in Internal Medicine since July 2008, Chief Supervisor for 24 graduated PhD students, more than 600 published original papers in peer reviewed journals. Professor Lind is mainly performing epidemiological research on risk factors and aetiology of different cardiovascular diseases, nowadays including GWAS, epigenetics, proteomics and metabolomics. PI (or co-PI) of the cohort studies PIVUS, POEM, EpiHealth and SCAPIS.

Thomas F. Lüscher

Zurich, Switzerland

EPIDEMIOLOGY, DIAGNOSIS, PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

Prognostics in patients with manifest (acute or chronic) CHD

Professor Lüscher studied medicine at the University of Zurich and obtained a board certification in internal medicine as well as cardiology. He trained in cardiovascular research as well as in echocardiography at the Mayo Clinic in Rochester, MN, USA and was later Professor of Pharmacotherapy at the University of Basel, then Professor of Cardiology at the University of Berne, before assuming his current position as Professor and Chairman of Cardiology at the University Hospital Zurich and Director of the Center for Molecular Cardiology at the University of Zurich, Switzerland. Since 2014, he is also directs the newly founded University Heart Center at his institution together with his surgical collegue Prof. Francesco Maisano.

In addition to his administrative responsibilities, Professor Lüscher is an active general and
interventional cardiologist. His research interests focus on the role of endothelium-derived mediators in the regulation of vascular tone, platelet-vessel wall interactions, and coagulation as well as vascular structure in aging, hypertension, hyperlipidemia, and atherosclerosis. The mission of his clinical research is the translation of basic research to humans, in particular in patients with hypertension, hyperlipidemia, coronary artery disease, inflammatory conditions, acute coronary syndromes, and heart failure.

Professor Lüscher has published extensively, authoring or co-authoring over 500 original research articles and over 200 review articles, bookchapters and monographs including the ESC Textbook of Cardiovascular Medicine. By the Institute for Scientific Information he has been rated as one of the 0.5% most cited scientists worldwide. He has obtained numerous research prizes and prestigious lecturerships. He is a member of many editorial boards and was Associate Editor Europe of Circulation from 2004 to 2008. Since 2009 he is chairman of the publications committee of the European Society of Cardiology (ESC) and an ex-officio member of the ESC board as well as editor-in-chief of the European Heart Journal.

Federica Marelli-Berg

London, United Kingdom

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

Metabolic pathways in immune cells

Federica Marelli-Berg qualified in Medicine and Surgery at the University of Milan in 1989, and specialized in Hematology in 1993 at the University of Pavia, Italy. In 1997 she completed her PhD studies at the Royal Postgraduate Medical School (London) under the supervision of Professor R. Lechler. In 2000 she was awarded a Governors’ lectureship by Imperial College London, where she continued her academic career to become Professor of Immunology in 2011. She joined the WHRI  (Barts and The London SMD, QMUL) in November 2011. In 2016 she was awarded a BHF Chair in Cardiovascular Immunology.

Stephen Nicholls

Adelaide, Australia

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

Advances in measuring plaque regression

ADVANCED CLINICAL SEMINARS

3D ultrasound

COMMUNICATION SESSIONS

Atherosclerosis regression: linking GLAGOV and FOURIER

COMMUNICATION SESSIONS

What do FOURIER data mean for clinical practice?

CARAT: WILL INFUSING A PRE-BETA HIGH-DENSITY LIPOPROTEIN MIMETIC (CER-001) REGRESS CORONARY ATHEROSCLEROSIS?

MILANO-PILOT: WILL INFUSING HDL MIMETICS CONTAINING APOA-IMILANO CONTINUE TO REGRESS CORONARY ATHEROSCLEROSIS IN THE MODERN ERA OF INTENSIVE STATIN THERAPY?

Stephen Nicholls is Deputy Director and Heart Health Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI). He is Professor of Cardiology at the University of Adelaide, Consultant Cardiologist at the Royal Adelaide Hospital and Principal Research Fellow of the National Health and Medical Research Council of Australia. He completed his medical training in Adelaide, cardiology training in Newcastle and his PhD at the Heart Research Institute, focusing on the anti-inflammatory properties of high-density lipoproteins (HDL, the good form of cholesterol). After a postdoctoral fellowship in plaque imaging, he was appointed to faculty at the Cleveland Clinic, where he served as the Medical Director of the Atherosclerosis Imaging Core Laboratory and Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research. He returned to Australia in 2012 to take up his current positions in Adelaide.

Professor Nicholls has published more than 600 original manuscripts, conference proceedings and book chapters, including in the New England Journal of Medicine, Lancet, Journal of the American Medical Association and Nature Medicine and is frequently invited to talk on a range of topics in cardiovascular disease at national and international conferences. He is currently a Past President of the Australian Atherosclerosis Society and Treasurer of the Cardiac Society of Australia and New Zealand and an inaugural  Fellow of the Australian Academy of Health and Medical Sciences.

Stephen Nicholls major research interests include studying the impact of metabolic factors influencing heart disease, development of novel plaque imaging modalities in clinical practice and performing large scale clinical trials of novel cardioprotective therapies.

Anders Nykjaer

Aarhus, Denmark

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

Sortilins: new players in cardiovascular and other metabolic diseases

Dr. Nykjaer is professor of medical biochemistry at Aarhus University. He is director of The Lundbeck Foundation Research Centre MIND and is heading NeuroCampus Aarhus, a research cluster in translational neuroscience comprising >500 scientists, aimed at bringing together basic and clinical research. Since 2014 he is also a professor at Mayo Clinic, Jacksonville. The theme of his research is functional aspects of Vps10p-domain receptors in health and disease. In particular, his research focuses on how receptor crosstalk regulates neuronal function and metabolic processes. This is accomplished by integrating biochemistry, cell biology, transgenic mouse models, gene therapy, electrophysiology, and mouse behavior.

Terje Pedersen

Oslo, Norway

COMMUNICATION SESSIONS

FOURIER: first outcomes data with a PCSK9 inhibitor

COMMUNICATION SESSIONS

What do FOURIER data mean for clinical practice?

Terje R. Pedersen, MD is professor emeritus (Preventive Cardiology) at the University of Oslo, Norway and retired Head of Research at the Centre for Preventive Medicine at Oslo University Hospital, Ullevål.

His main interest is in preventive cardiology and he has been the principal investigator in several major clinical trials like The Norwegian Timolol Trial, the Scandinavian Simvastatin Survival Study (4S) , the IDEAL study and the SEAS study.  He is Co-chair of the Executve Committee of the FOURIER trial, with 27 564  patients to study the effect of  evolocumab, a PCSK9 inhibitor, on the prognosis  in patients with CVD.

Matteo Pirro

Perugia, Italy

EBAC ACCREDITATION PENDING

The clinical evidence: Meta-analysis of the RCT

Kausik Ray

London, United Kingdom

ADVANCED CLINICAL SEMINARS

Case and panel discussion

ADVANCED CLINICAL SEMINARS

FH Collaboration Studies – FHSC registry

ADVANCED CLINICAL SEMINARS

On the panel:

siRNA to PCSK9 in patients with high Cardiovascular Risk and Elevated LDL-C: the ORION 1 Trial

The future – what does it hold?

Panel discussion

Kausik Ray is Professor of Public Heath, and Honorary Consultant Cardiologist at Imperial College London. Professor Ray received his medical education at the University of Birmingham Medical, his MD thesis at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and his MPhil in epidemiology from the University of Cambridge.A Fellow of the ACC, ESC, AHA, and the RCP (London and Edinburgh).

His research interests have focused on the prevention of CVD from large scale observational studies to clinical trials. His work has influenced international guidelines and received more than 12 000 citations.

Professor Ray leads the EAS FH Studies collaboration involving around 60 countries currently and serves on the Executive Committee of several ongoing trials in cardiovascular disease.  

Patrick Rensen

Leiden, Netherlands

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

Brown adipose tissue: a novel target to comBAT cardiometabolic disease

Patrick C.N. Rensen is professor Metabolic Aspects of Vascular Disease at LUMC. He is Established Investigator of the Dutch Heart Foundation, chairs the Dutch Lipoprotein Club (NLC) and is board member the European Lipoprotein Club (ELC). His research focuses on brown adipose tissue (BAT) activation as a strategy to comBAT obesity, type 2 diabetes and cardiovascular disease. He currently investigates novel targets that modulate BAT activity including the immune system and the biological clock, and searches for novel non-invasive techniques and biomarkers to quantify BAT activity, by combining BAT-targeted intervention studies with the large Netherlands Epidemiology of Obesity (NEO) cohort.

Gabriele Riccardi

Naples, Italy

EBAC ACCREDITATION PENDING

The new EAS/ESC Guidelines on diet and lifestyle in cardiovascular prevention

Gabriele Riccardi is Full Professor of Endocrinology and Metabolic Diseases at the “Federico II” University in Naples, Italy, where he is Director of the Master Course in Human Nutrition and Head of the Diabetes, Nutrition and Metabolism Unit of the University Hospital. He was President of the Società Italiana di Diabetologia (SID) from 2010 to 2012. Author of over 300 in extenso publications in international scientific journals listed in Pub Med (total impact factor > 600), he has an H index of 54. He has been awarded the Celso Prize from the Italian Diabetes Society in 2016 for the outstanding contribution to diabetes research during his academic career.

Emilio Ros

Barcelona, Spain

EBAC ACCREDITATION PENDING

Updates on the guidelines. Which role for nutraceuticals?

Former director, Lipid Clinic, Endocrinology Service, Hospital Clínic, Barcelona; Emeritus Investigator IDIBAPS; PI of research group, CIBER Fisiopatología de Obesidad y Nutrición, Instituto de Salud Carlos III, Spain. Postgraduate training in New York and Boston (1970-1976). American Boards of Internal Medicine and Gastroenterology. Member of Spanish Atherosclerosis Society (SEA), EAS, IAS, ISSFAL, and ACC. Various awards to best scientific career in Nutrition. Research in nutrition for CVD prevention, including Mediterranean diet (PREDIMED trial), walnuts and phytosterols; cognitive function; membrane fatty acids; genetic dyslipidemias; cardiovascular risk assessment; vascular imaging. Publications: over 320 original papers and 125 review papers in peer-reviewed journals.

Frank A. J. L. Scheer

Boston, USA

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

Circadian control of metabolism

Frank A.J.L. Scheer, PhD is Associate Professor of Medicine at Harvard Medical School and the Director of the Medical Chronobiology Program at Brigham and Women’s Hospital. Dr. Scheer’s team focuses on influences of the endogenous circadian system and its disruption—such as with shift work—on cardiovascular, pulmonary and metabolic regulation, and disease states, such as hypertension, asthma, obesity and diabetes. Dr. Scheer has received numerous awards, including AASM’s Young Investigator Award, NSF’s First Place Clinical Research Young Investigator Award, and ABMR’s Neal Miller Award. Dr. Scheer is a Board/Program Member of the European Society of Biological Rhythms, Society of Research on Biological Rhythms, and Associated Professional Sleep Societies LLC.

Ursula Schwab

Kuopio, Finland

EBAC ACCREDITATION PENDING

Nordic and Mediterranean diet patterns from the CVD point of view

Ursula Schwab, PhD, is Professor (nutrition therapy) at the University of Eastern Finland (UEF). She works also as a clinical nutritionist at the Kuopio University Hospital. Her expertise is in planning and conducting randomized controlled dietary interventions regarding e.g. the effects of dietary fat, fish, berries and whole grain products, and the healthy Nordic dietary pattern on lipid and glucose metabolism including nutrigenomics, lipidomics and metabolomics approaches. Her research group is partly funded by the Spearhead funding of UEF. She has been involved in the updating of the Nordic and Finnish Nutrition Recommendations, several national good practice guidelines, and the European dietary guidelines for diabetic patients.

Reena Sharma

Salford, United Kingdom

EBAC ACCREDITATION PENDING

Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency

Dr Reena Sharma is the clinical lead for adult Metabolic Services at The Mark Holland Metabolic Unit, Salford Royal Hospital NHS Foundation Trust, Greater Manchester UK. She is also an Honorary Senior Lecturer University of Manchester, UK, and an external advisor to the Scottish Government for the creation and development of Metabolic services in Scotland.

She has a been consultant for more than 5 years and has served, and continues to serve, as principle and chief investigator for multiple commercial and non-commercial national and international clinical studies as well as supervising MSc and PhD research projects.

The Mark Holland Metabolic unit has the largest volumes of metabolic patients in the UK. Therefore in the role of clinical lead, Dr Reena Sharma oversees some of the largest numbers of patients in these disease groups in the UK. This includes extensive experience with a large number of Lysosomal Storage Disorder (LSD) patients that inlcude Fabry, Gaucher, MPS, NPC, Pompe (GSD 2), Cystinosis etc. This also extends to general metabolic patients that include large cohorts of PKU, Homocystinuria, Urea Cycle Defects, Fatty Acid Oxidations defects, Organic Acidaemia, Glycogen Storage Disorders (GSDs) and other rare disorders.

 

Jason M. Tarkin

London, United Kingdom

ADVANCED CLINICAL SEMINARS

CT angiography

Jason Tarkin is currently a Cardiology Registrar at the Barts Heart Centre in London, UK, having recently completed a Wellcome Trust funded Clinical Research Training fellowship at the University of Cambridge. His PhD research, based at Addenbrooke’s Hospital, was focused on PET-CT imaging of vascular inflammation in atherosclerosis. Dr. Tarkin is a Member of the Royal College of Physicians, and during his medical training he worked at Hammersmith, Royal Brompton and Harefield Hospitals. He graduated with Distinction in Clinical Sciences from St George’s, University of London in 2008, and was awarded summa cum laude with Honors in Biology from the University of New Hampshire, USA in 2003. Most recently, he was the recipient of the American Heart Association Melvin Judkins Young Clinical Investigator Award in Cardiovascular Radiology at the 2016 Scientific Sessions in New Orleans. 

Lale Tokgözoğlu

Ankara, Turkey

ADVANCED CLINICAL SEMINARS

Case and panel discussion

ADVANCED CLINICAL SEMINARS

On the panel:

EBAC ACCREDITATION PENDING

Combination therapy a better way to treat?

Conclusion: Translating science for the benefit of patients

Roundtable and Q&A

Introduction

S. Lale Tokgözoğlu, M.D., F.A.C.C., F.E.S.C. was born in 1959 in Ankara, Turkey. She graduated from the Hacettepe University Faculty of Medicine in 1982 on the honor roll. After finishing the Internal Medicine Residency program in the Hacettepe University Faculty of Medicine Department of Internal Medicine on 1988, she completed a fellowship program on Cardiology and Atherosclerosis at the Baylor College of Medicine in Houston, Texas. Dr. Tokgözoğlu returned to the Hacettepe University in 1991 to become Associate Professor of Cardiology, and later Professor of Cardiology in 1998.

Prof. Tokgözoğlu has served on the Executive Committee of the European Society of Atherosclerosis as member between 2003 and 2005 ,as Secretary between 2005-2009 and as Vice President of the European Atherosclerosis Society between 2009-2013. She is currently President-elect of the European Atherosclerosis Society. She was the President of the 77th European Atherosclerosis Society meeting in İstanbul.

She also served as the President of the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010.  She has served for 2 years on board of the European Society of Cardiology Fellowship and Training Committee and for 2 years on the board of the Education Committee. She has also served first as Member-at-Large (Europe) of the Executive Committee of the International Society of Atherosclerosis, then as President of the European Federation of the International Atherosclerosis Society followed by the post of  Secretary of the International Society of Atherosclerosis. She is still serving on their executive committee.

Prof. Tokgözoğlu has served on the Board of the Prevention Association of the European Society of Cardiology since 2011. She will be the chair of the Europrevent Congress in 2016 in İstanbul. Prof Tokgözoğlu has founded and chaired the Istanbul Consortium Chapter of the American College of Cardiology in 2010 which is a consortium of 16 countries. She was elected to be the European representative of the American College of Cardiology Assembly of International Governors Steering Committee in 2015.

She has been serving on the Scientific Program Committee of European Society of Cardiology since 1995. She has been a member of the young investigator award committees of the International Atherosclerosis Society in Stockholm 2000,  European Atherosclerosis Society in Prague in 2005 and European Society of Cardiology in 2009, 2010 and 2015. Prof. Tokgözoğlu is currently a Fellow of the American College of Cardiology and European Society of Cardiology.

Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014. Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and  as  Vice President between 2008 and 2010 and is currently the President of the Turkish Society of Cardiology.  

She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof  Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey.

Prof Tokgözoğlu initiated the academic collaboration between Cornell-Weill Medical College and Hacettepe Universities in 2013 and is the Coordinator for the Cornell-Weill Medical College affairs in Hacettepe University.

Prof Tokgözoğlu has more than 200 publications, has authored 3 books and several book chapters. Prof. Tokgözoğlu is on the Editorial Board for European Heart Journal, Atherosclerosis, Anatolian Journal of Cardiology and Archives of the Turkish Society of Cardiology.  She has won the “Prof. Dr. Şeref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994 and second runner up in the Pfizer Cardiology Scientific Award in 1999.

Prof Tokgözoğlu works and publishes on atherosclerotic vascular disease, clinical lipidology, imaging ,hypertension and pulmonary hypertension.

 

 

Alexandros Tselepis

Ioannina, Greece

ADVANCED CLINICAL SEMINARS

Case and panel discussion

ADVANCED CLINICAL SEMINARS

On the panel:

Alexandros D. Tselepis MD, PhD, is Professor of Biochemistry–Clinical Chemistry in the University of Ioannina and Director of the Atherothrombosis Research Centre of the same University. Professor Tselepis’ main scientific interests are in the pathophysiology of Atherothrombosis and he has participated in several European and National Research Networks. He has more than 230 publications at international journals and more than 5,400 citations, whereas his current h-index is 39. Alexandros Tselepis is Editor of the Hellenic Journal of Atherosclerosis and member of the Editorial Boards of various international journals. Professor Tselepis is member of the Hellenic Atherosclerosis Society Executive Committee, General Secretary of the Institute for the Study and Education on Thrombosis and Antithrombotic Therapy and has been recently elected as member of the European Atherosclerosis Society Executive Committee.

Sotirios Tsimikas

San Diego, USA

EPIDEMIOLOGY, DIAGNOSIS, PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

Hypertriglyceridaemia: ApoC-III and ANGPTL3

Dr. Tsimikas is Professor of Medicine and Director of Vascular Medicine at the University of California San Diego. He obtained his MD degree in 1988 from the University of Massachusetts Medical School. He completed Internal Medicine training at the University of Massachusetts Medical Center in 1991, and fellowships in Cardiovascular Disease, Atherosclerosis and Molecular Medicine and Interventional Cardiology at the University of California San Diego from 1992-1997. Dr. Tsimikas’ clinical interests Vascular Medicine Program encompass treating patients in the continuum of high-risk primary prevention to endovascular intervention.

Jaakko Tuomilehto

Kuwait City, Kuwait

ICCR-EAS Joint Session

Preventing Type 2 Diabetes by lifestyle: an under-recognised/under-used approach in clinical practice

Professor Emeritus at Helsinki University, Finland is currently working as the Chief Scientific Officer at Dasman Diabetes Institute in Kuwait. His research interests include non-communicable diseases such as diabetes, cardiovascular disease, cancer and dementia.

He has contributed many landmark studies, including the North Karelia Project, WHO MONICA Project, Finnish Diabetes Prevention Study. He has served for ADA, ESC and WHO committees on diabetes and cardiometabolic risk. He has contributed to over 1600 scientific peer-reviewed publications, and is one of the most cited authors in the field of clinical medicine, and molecular biology and genetics worldwide with h-index 155.

Michal Vrablík

Prague, Czech Republic

EBAC ACCREDITATION PENDING

Fibrates in the management of AD and CVD risk

The evidence – what’s new?

Panel discussion

Concluding remarks

Michal Vrablik M.D., Ph.D. is currently an Associate Professor of Internal Medicine at the 1st Faculty of Medicine, Charles University in Prague, the Czech Republic. His main interests include preventive cardiology, clinical lipidology and genetics of lipoprotein metabolism disorders.

After graduating from the 1st Faculty of Medicine of Charles University in Prague in 1997 he obtained his PhD in 2001 (thesis on “Familial Dyslipidemias – Clinical and Genetic Aspects”). In 2011 he successfully defended his habilitation work and was appointed an Associate Professor in Internal Medicine. He is most recently involved in studying cardiovascular prevention strategies in different population groups and pharmacogenetic studies.

He is the chairman of the Czech Atherosclerosis Society, a member of the Executive Committee of the European Atherosclerosis Society and, also, a member of the board of the Czech Society of Internal Medicine and the board of the Working group of preventive cardiology of the Czech Society of Cardiology. He participates in the FH screening MedPed program being a leader of the project’s national center. He has served as a principal investigator and investigator in more than thirty research projects on familial dyslipidemias and cardiovascular disease risk and has participated in a number of international clinical trials.

Dr. Vrablik regularly presents at national as well as international scientific meetings and he is also involved in the “Speakers Bureau” for IAS- European Federation. Dr. Vrablik served as a lecturer at the EAS Summer School between 2007 and 2009. Since 2010 he has worked as a co-organizer of International Atherosclerosis Research School endorsed by the EAS and IAS. He was a member of organizing committees of the 75th EAS congress in Prague in 2005 and the 12th Congress of European Federation of Internal Medicine in 2013. He is the Congress Chair of the 85th Congress of European Atherosclerosis Society to be held in Prague in 2017.

In 2005-6 he received a research grant from the Czech Society of Cardiology and joined Healthy Heart Program of St. Paul´s Hospital, Vancouver, Canada. He worked at Cardiovascular Risk Reduction and Metabolic Syndrome Clinics with prof. Jiri Frohlich.

Dr. Vrablik has authored and co-authored more than 100 papers in peer-reviewed scientific journals. He is the sole author of two monographs and of fifteen book chapters. He is also a member of editorial board as well as a reviewer for several national and international journals.

Gerald Watts

Perth, Australia

ADVANCED CLINICAL SEMINARS

Title TBA

KEYNOTE LECTURE

Keynote Lecture: Mechanistic insights into innovative therapeutics in lipid lowering in vivo

Gerald F Watts is a senior consultant physician, university professor and chair of The Familial Hypercholesterolaemia-Australasia Network. He trained at Imperial and King’s Colleges in the University of London before moving to Australia. He is currently director of the Metabolic Research Centre, Cardiometabolic Services (Department of Cardiology) and Head of the School of Medicine and Pharmacology Unit (University of Western Australia) and Professor of Cardiometabolic Medicine on the Royal Perth Hospital campus. Research interests include lipid disorders, obesity and cardiovascular prevention, and clinical interest focuses on delivering improved health care for FH and related conditions. Professor Watts is actively involved in teaching and supervisors several MD and PhD students and post-doctoral fellows. He has authored over 500 published works and is on the editorial board of Atherosclerosis, Clinical Science, Metabolism, Journal of Clinical Lipidology, and Current Opinion in Lipidology.

Christian Weber

Munich, Germany

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis

Christian Weber is the Chair in Vascular Medicine and Director of the Institute for Cardiovascular Prevention at Ludwig‐Maximilians‐University Munich, and also serves as an Adjunct Professor at the Cardiovascular Research Institute Maastricht. His group has a strong interest in the molecular interactions, pathophysiological functions and therapeutic targeting of chemokines, microRNAs and immune cells in atherosclerosis. Among many awards, he is a double ERC Advanced Investigator with more than 480 publications and an h‐index of 85, acts as Spokesman of the DFG Collaborative Research Centre SFB1123 on Atherosclerosis and coordinates the Munich Heart Alliance within the German Centre for Cardiovascular Research.

Olov Wiklund

Gothenburg, Sweden

ADVANCED CLINICAL SEMINARS

Case and Panel discussion

ADVANCED CLINICAL SEMINARS

On the panel:

Olov Wiklund is Professor Emeritus at the Sahlgrenska Academy at the University of Gothenburg, and previous Head of the Department of Cardiology, at Sahlgrenska University Hospital in Gothenburg, Sweden.  As a distinguished cardiologist, he was a member of the writing group for the EAS/ESC Guidelines for the Management of Dyslipidaemia 2011 and 2016,  and a reviewer for the European Guidelines on Cardiovascular Prevention in Clinical Practice (2016 version). He has held several positions in national and international organisations in the field of atherosclerosis and cardiovascular disease. Until 2016 he was Vice-President of the EAS. His main research interest is dyslipidaemia in cardiovascular prevention and disease with a focus on the interaction between lipoproteins and the vascular wall.

Alberto Zambon

Padova, Italy

ADVANCED CLINICAL SEMINARS

Title TBA

EBAC ACCREDITATION PENDING

Atherogenic dyslipidemia (AD)

Professor Alberto Zambon received his MD degree in 1988 from the University of Padua. He is board certified in endocrinology and metabolism (1993), and holds a PhD in gerontology from the University of Padua (1998).

Professor Zambon was a Post-Doctoral Fellow in Endocrinology and Metabolism at the Division of Endocrinology, Metabolism and Nutrition, School of Medicine, University of Washington, Seattle, (1991-1993 and again 1995-1998) where he currently is an Affiliate Assistant Professor of Medicine.

Professor Zambon received several honors, scholarships and fellowships and among them an AHA fellowship award (1996-97), the 1997 Young Faculty Award of the Western Society for Clinical Investigation (US), the Paul Beeson Physician Faculty Scholarship of American Federation For Aging Research (1998-2001).

He has authored or co-authored more than 80 peer-reviewed publications and 5 book chapters, and has delivered more than 160 invited lectures.

Professor Zambon is currently a member of the national board of the Italian Atherosclerosis Society Foundation. He is a member of the Italian Atherosclerosis Society (SISA), the European Atherosclerosis Society (EAS), and the International Atherosclerosis Society (IAS). He has served as member of the the International Advisory Board for the XV and XVI International Atherosclerosis Society (IAS) Symposiums. Professor Zambon is currently the chair of the IAS Regional Federation for Europe.

Noam Zelcer

Amsterdam, Netherlands

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

Deubiquitylase USP2 and LDL-R biology

Noam Zelcer obtained his B.Sc at the Hebrew University in Jerusalem, followed by an M.Sc at the free university in Amsterdam. He conducted his PhD work at the Netherlands Cancer Institute where he studied the role of ABC transporters in multidrug resistance of tumors. Between 2003-2008 he worked as a postdoctoral fellow at HHMI/UCLA investigating the transcriptional regulation of lipid metabolism. From 2009 he is a group leader at the Academic Medical Centre of the University of Amsterdam. Research in his group focuses on the role of the ubiquitin proteasomal system in lipid and energy metabolism.

 

Tanja Zeller

Hamburg, Germany

ESC-EAS Joint Session

Circulating miRNA for cardiovascular death prediction

Prof. Dr. Tanja Zeller is Professor for Genomics and Systems Biology and is leading the molecular cardiology research team at the UKE with the particular interest on emerging molecular biomarkers such as non-coding RNAs and translational aspects. She has longstanding experience in biomarker research and is coordinator of the BMBF-funded e:Med symAtrial consortium, PI of the EU BiomarCaRE Project and PI of several Omics and whole genome sequencing projects. Prof. Zeller is speaker of the BMBF e:Med and DZHK OMICS and systems medicine committee. Furthermore, Prof. Dr. Zeller is head of the CCS and HCHS Biobank and the biobanking working group at the DZHK.